Nuvectis Pharma (NASDAQ:NVCT) Sees Unusually-High Trading Volume – Here’s Why

Nuvectis Pharma, Inc. (NASDAQ:NVCT) shares saw unusually-strong trading volume on Thursday . 97,202 shares changed hands during trading, an increase of 7% from the previous session’s volume of 90,796 shares.The stock last traded at $24.62 and had previously closed at $24.48.

Analyst Upgrades and Downgrades

NVCT has been the topic of several analyst reports. Wall Street Zen upgraded shares of Nuvectis Pharma from a “sell” rating to a “hold” rating in a report on Saturday, May 9th. HC Wainwright upped their price objective on shares of Nuvectis Pharma from $13.00 to $39.00 and gave the company a “buy” rating in a research report on Monday. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Nuvectis Pharma in a research note on Friday, June 5th. One research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus price target of $39.00.

Nuvectis Pharma Trading Up 7.4%

The business has a 50 day moving average of $10.70 and a 200-day moving average of $9.13. The firm has a market capitalization of $697.47 million, a P/E ratio of -20.07 and a beta of -0.07.

Nuvectis Pharma (NASDAQ:NVCT) last announced its quarterly earnings results on Tuesday, May 5th. The company reported ($0.26) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.30) by $0.04. On average, analysts anticipate that Nuvectis Pharma, Inc. will post -1.01 EPS for the current fiscal year.

Hedge Funds Weigh In On Nuvectis Pharma

Large investors have recently added to or reduced their stakes in the company. Iridian Asset Management LLC CT lifted its holdings in shares of Nuvectis Pharma by 44.5% in the fourth quarter. Iridian Asset Management LLC CT now owns 586,320 shares of the company’s stock valued at $4,427,000 after purchasing an additional 180,699 shares in the last quarter. Occam Crest Management LP grew its holdings in shares of Nuvectis Pharma by 31.0% during the fourth quarter. Occam Crest Management LP now owns 380,000 shares of the company’s stock worth $2,869,000 after buying an additional 90,000 shares in the last quarter. Oppenheimer & Co. Inc. grew its holdings in shares of Nuvectis Pharma by 6.5% during the fourth quarter. Oppenheimer & Co. Inc. now owns 73,566 shares of the company’s stock worth $555,000 after buying an additional 4,500 shares in the last quarter. Baldwin Wealth Partners LLC MA raised its position in Nuvectis Pharma by 11.2% in the 4th quarter. Baldwin Wealth Partners LLC MA now owns 389,625 shares of the company’s stock valued at $2,942,000 after buying an additional 39,164 shares during the last quarter. Finally, State Street Corp raised its position in Nuvectis Pharma by 13.1% in the 4th quarter. State Street Corp now owns 154,666 shares of the company’s stock valued at $1,168,000 after buying an additional 17,950 shares during the last quarter. Institutional investors own 96.77% of the company’s stock.

About Nuvectis Pharma

Nuvectis Pharma is a clinical-stage biotechnology company focused on the development of novel peptide-based therapeutics using its proprietary Cellporting delivery platform. The company’s core technology is designed to facilitate the transport of therapeutic proteins and peptides across cellular membranes and into target intracellular compartments, including the nucleus. By overcoming a key barrier in biologics delivery, Nuvectis aims to expand the range of treatable diseases with macromolecular drugs that have traditionally been limited by poor cellular uptake.

The Nuvectis pipeline encompasses multiple preclinical and early-stage clinical programs targeting rare genetic and metabolic disorders.